JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.
Cell lines
Rat isolated hepatocytes
Reaction Conditions
1.12 nM (IC50)
Applications
Rosuvastatin inhibited the incorporation of sodium [14C]acetate into cholesterol with an IC50 value of 1.12 nM, and its inhibitory activity on cholesterol biosynthesis was approximately 100 times more potent than pravastatin.
Animal models
Normolipemic male beagle dogs
Dosage form
3 mg/kg/day
Administered orally for 14 days
In male beagle dogs with normal cholesterol levels, rosuvastatin (3 mg/kg/day) administration for 14 days decreased plasma cholesterol levels by 26%, higher than 18% in the pravastatin treatment group.
Note
The technical data provided above is for reference only.
References:
1. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorganic & Medicinal Chemistry, 1997, 5(2): 437-444.